PhRMA Comments to USPTO on Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting

The Pharmaceutical Research and Manufacturers of America (PhRMA) is pleased to submit these comments in response to the United States Patent and Trademark Office's (USPTO) Notice of Proposed Rulemaking on Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting (May 10, 2024).